A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and endometrial cancers, with several in late-stage trials. Key players like Merck, Roche, and Pfizer are advancing promising candidates, while regulatory approvals and breakthrough designations signal strong growth potential. This expanding pipeline highlights ongoing innovation and competition in oncology treatments, promising improved patient outcomes and new market opportunities.
The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a Buy due to its mix of high-quality dividend-paying stocks like ABT, UNH, and MRK, which offer strong dividend growth and underappreciated catalysts. The fund's defensive sector focus and ...
Merck & Co. maintains a Strong Buy rating due to its expanding oncology pipeline and the launch of LIPFENDRA, the first oral PCSK9 inhibitor aimed at patients needing additional LDL cholesterol reduction beyond statins. The company’s oncology progres...
Health stocks Eli Lilly (LLY), United Health Group (UNH), and Merck (MRK) have recently seen positive developments, including drug approvals and strong earnings. These gains have boosted their stock prices, with LLY up over 8% YTD, UNH up 25.8% YTD, ...
Merck & Co. reported a 4.9% revenue increase to $16.29 billion in Q1 2026, driven by strong sales of its cancer drug Keytruda, which rose 8% to $8 billion. The company also raised its full-year revenue and earnings per share guidance to $67 billion a...
